Echo IQ Limited is an Australian medical technology company specializing in artificial intelligence-driven decision support for cardiology. The company develops software that analyzes routine echocardiographic measurements to help clinicians identify structural heart diseases, with a particular focus on conditions such as aortic stenosis and heart failure. Its core platform, EchoSolv, is classified as Software as a Medical Device and is designed to deliver rapid, consistent risk assessments without requiring direct image analysis, integrating into existing echocardiography workflows to support diagnosis and triage decisions. Echo IQ Limited works closely with hospitals, cardiology practices, and healthcare partners in markets including Australia and the United States, where its solutions are used as decision-support aids to improve detection of high-risk patients and streamline clinical workflows. Founded in 2010 and headquartered in Sydney, Australia, the company operates within the broader digital health and AI diagnostics segment, providing tools that support more efficient and standardized cardiovascular care.